Business
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD. Details of the poster presentation are as follows: Title: A Phase II Trial of Combination Locoregional
About this update from Aim Immunotech Inc.
[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ExfZBbISk6KxGeFYkBNhew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD.","length":401,"tagName":"p"},{"type":"text","content":"Details of the poster presentation are as follows:","length":50,"tagName":"p"},{"type":"text","content":"Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical OutcomesPresenting Author: Mackenzy M. Radolec, MD, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women’s HospitalAbstract Number: 1343Date: Friday, November 7, 2025Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center","length":495,"tagName":"p"},{"type":"text","content":"For more information about the SITC Annual Meeting, please visit sitcancer.org.","length":79,"tagName":"p"},{"type":"text","content":"About AIM ImmunoTech Inc.","length":25,"tagName":"p"},{"type":"text","content":"AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.For more information, ple...